xyzal

Levocetirizine Dihydrochloride (Xyzal Dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Acting as an antihistaminic agent, it specifically targets the histamine H1-receptor. Levocetirizine Dihydrochloride is the R-enantiomer of Cetirizine, which gives it a higher affinity for the H1-receptor than the S-enantiomer. Due to this enhanced affinity, Levocetirizine Dihydrochloride is effective in treating allergic rhinitis and chronic idiopathic urticaria.

Cetirizine D8 dihydrochloride is a deuterium-labeled Cetirizine. Cetirizine is a second-generation antihistamine and a long-acting histamine H1-receptor antagonist.

Cetirizine D4 is a deuterium-labeled Cetirizine. Cetirizine is a second-generation antihistamine and a long-acting histamine H1-receptor antagonist.

Cetirizine D8 is a deuterium-labeled Cetirizine. Cetirizine is a second-generation antihistamine and a long-acting histamine H1-receptor antagonist.

Levocetirizine is a Histamine-1 Receptor Antagonist. The mechanism of action of levocetirizine is as a Histamine H1 Receptor Antagonist.

Cetirizine dihydrochloride (UCB P071) is an effective second-generation histamine H1 antagonist that is potent in the therapy of allergic rhinitis, confirmed urticaria, and pollen-induced asthma. Unlike other conventional antihistamines, it does not cause side effects of drowsiness or anticholinergic.